🧬 Interested in pharma, biotech and medical device news? Visit PharmaDeviceNews.com →

AbbVie completes acquisition of Landos Biopharma to strengthen immunology portfolio

AbbVie wraps up strategic acquisition of Landos Biopharma for $137.5 million to enhance its immunology portfolio and promises advancements in IBD treatment.
AbbVie wraps up strategic acquisition of Landos Biopharma for $137.5 million to enhance its immunology portfolio and promises advancements in IBD treatment.